Literature DB >> 8110924

Fluconazole-resistant Candida albicans.

D J Boken1, S Swindells, M G Rinaldi.   

Abstract

Mucocutaneous candidiasis caused by Candida albicans is a common complication of human immunodeficiency virus (HIV) infection. Recent reports of isolation of resistant strains of C. albicans raise the specter of more widespread resistance, but limited series are available to analyze situations in which the likelihood of resistance is greatest. We present our experience with fluconazole-resistant candidiasis in patients with HIV infection obtained from retrospective chart review and by testing strains of C. albicans isolated during relapse for susceptibility to antifungal agents. The possible reasons for failure of antifungal therapy are discussed, as well the correlation between in vivo and in vitro data. Resistant candidiasis in patients with HIV disease is an emerging problem of considerable concern that merits further study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110924     DOI: 10.1093/clinids/17.6.1018

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.

Authors:  Hua Quan; Ying-Ying Cao; Zheng Xu; Jing-Xia Zhao; Ping-Hui Gao; Xiao-Feng Qin; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 2.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

Authors:  H M Wardle; D Law; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

Authors:  F Barchiesi; L Falconi Di Francesco; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

6.  Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

Authors:  F Barchiesi; L K Najvar; M F Luther; G Scalise; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 7.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.

Authors:  F Lacassin; F Damond; C Chochillon; P Longuet; J Lebras; J L Vilde; C Leport
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.